TPG-backed drugmaker Aptalis files for IPO of up to $500 million-Reuters
Specialty drugmaker Aptalis Holdings Inc, owned by private equity firm TPG Capital LP, filed with U.S. regulators to raise up to $500 million in an initial public offering of its common stock, Reuters reported.
26 December 2013•1 min read
